Vanda Pharmaceuticals Inc. (VNDA) Form 10-Q — Oct 29, 2026
Vanda Pharmaceuticals reported Q3 2026 revenue of $69.8 million, up 24% year-over-year, driven by Fanapt momentum (total prescriptions up 25%) and the first $1.6 million of NEREUS sales following its May 2026 U.S. launch. HETLIOZ contributed $21.7 million, though this included roughly $7.0 million of revenue from orders shipped just before quarter-end. Despite the revenue growth, the quarter's net loss of $22.6 million was roughly flat versus a year ago, and the nine-month net loss widened to $133.6 million from $79.3 million, with operating cash burn of $109.7 million.
Key figures
- Revenue
- 69815000
- Revenue Yoy
- 24% (Q3); 8% (nine months to $172.1M)
- Total Assets
- 382327000
- Cash Position
- 61933000
- Shares Outstanding
- 60469687
- Rd expense q3
- 27622000
- Sga expense q3
- 59575000
- Q3 2025 revenue
- 56258000
- Nine month revenue
- 172062000
- Stockholders equity
- 199858000
- Prior year end liquidity
- 263847000
- Total cash and marketable securities
- 140494000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.